Hypersensitivity, Immediate Recruiting Phase 3 Trials for Fevipiprant (DB12011)

Also known as: Type I Hypersensitivity / Immediate Hypersensitivity / Hypersensitivity type I / Hypersensitivity type I NOS / Immediate hypersensitivity reaction

IndicationStatusPhase
DBCOND0031076 (Hypersensitivity, Immediate)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03629249Systemic Corticosteroids Avoidance Study in Severe Asthma PatientsTreatment